1

Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil

2

3	William Marciel de Souza ¹ *, Lewis Fletcher Buss ² *, Darlan da Silva Candido ³ *, Jean-Paul
4	Carrera ^{3,4} *, Sabrina Li ⁵ *, Alexander E. Zarebski ³ , Rafael Henrique Moraes Pereira ⁶ , Carlos
5	A. Prete Jr ⁷ , Andreza Aruska de Souza-Santos ⁸ , Kris V. Parag ⁹ , Maria Carolina T.D.
6	Belotti ⁷ , Maria F. Vincenti-Gonzalez ¹⁰ , Janey Messina ^{5,11} , Flavia Cristina da Silva Sales ² ,
7	Pamela dos Santos Andrade ² , Vítor Heloiz Nascimento ⁷ , Fabio Ghilardi ² , Leandro Abade ³ ,
8	Bernardo Gutierrez ^{3,12} , Moritz U. G. Kraemer ^{3,13,14} , Carlos K.V. Braga ⁶ , Renato Santana
9	Aguiar ¹⁵ , Neal Alexander ¹⁶ , Philippe Mayaud ¹⁷ , Oliver J. Brady ^{15,18} , Izabel Marcilio ¹⁹ ,
10	Nelson Gouveia ²⁰ , Guangdi Li ²¹ , Adriana Tami ¹⁰ , Silvano Barbosa de Oliveira ²² , Victor
11	Bertollo Gomes Porto ²² , Fabiana Ganem ²² , Walquiria Aparecida Ferreira de Almeida ²² ,
12	Francieli Fontana Sutile Tardetti Fantinato ²² , Eduardo Marques Macário ²³ , Wanderson
13	Kleber de Oliveira ²³ , Mauricio L. Nogueira ²⁴ , Oliver G. Pybus ³ , Chieh-Hsi Wu ²⁵ *, Julio
14	Croda ^{23,26,27,28} * [#] , Ester C. Sabino ² *, Nuno Rodrigues Faria ^{3,29} * [#]

15 * These authors contributed equally

16 # Corresponding author

17

Centro de Pesquisa em Virologia, Faculdade de Medicina de Ribeirão Preto, Universidade
 de São Paulo, Ribeirão Preto, Brazil.

20 2. Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo,

21 São Paulo, Brazil.

- 22 3. Department of Zoology, University of Oxford, Oxford, UK.
- 23 4. Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of
- 24 Health Studies, Panama City, Panama.

- 25 5. School of Geography and the Environment, University of Oxford, Oxford, UK.
- 26 6. Institute for Applied Economic Research (IPEA), Brasília, Brazil.
- 27 7. Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
- 28 8. Brazilian Studies Programme, Latin American Centre, University of Oxford, Oxford, UK.
- 29 9. MRC Centre for Global Infectious Disease Analysis, Imperial College London, UK.
- 30 10. University of Groningen, University Medical Center Groningen, Department of Medical
- 31 Microbiology and Infection Prevention, Groningen, Netherlands.
- 32 11. Oxford School of Global and Area Studies, University of Oxford, Oxford, UK.
- 33 12. School of Biological and Environmental Sciences, Universidad San Francisco de Quito
- 34 USFQ, Quito, Ecuador.
- 35 13. Harvard Medical School, Harvard University, Boston, MA, USA.
- 36 14. Boston Children's Hospital, Boston, MA, USA.
- 37 15. Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas,
 38 Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
- 39 16. MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology,
- 40 Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical
 41 Medicine, London, UK.
- 42 17. Department of Clinical Research, Faculty of Epidemiology and Population Health,
- 43 London School of Hygiene & Tropical Medicine, London, UK.
- 44 18. Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious
- 45 Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
- 46 19. Núcleo de Vigilância Epidemiológica do Hospital das Clínicas da Faculdade de Medicina,
- 47 Universidade de São Paulo, São Paulo, Brazil.
- 48 20. Departamento Medicina Preventiva, Faculdade de Medicina da Universidade de São
 49 Paulo, São Paulo, Brazil.

- 50 21. Department of Epidemiology and Health Statistics, Xiangya School of Public Health,
- 51 Central South University, Changsha 410078, China.
- 52 22. Secretariat of Health Surveillance, Department of Immunization and Communicable
- 53 Diseases, Brazilian Ministry of Health, Brasília, Brazil.
- 54 23. Secretariat of Health Surveillance, Brazilian Ministry of Health, Brasília, Brazil.
- 55 24. Faculdade de Medicina de São José do Rio Preto, São Jose do Rio Preto, Brazil.
- 56 25. Mathematical Sciences, University of Southampton, Southampton, UK.
- 57 26. Laboratório de Pesquisa em Ciências da Saúde, Universidade Federal da Grande
 58 Dourados, Dourados, Brazil.
- 59 27. Fundação Oswaldo Cruz, Campo Grande, Mato Grosso do Sul, Campo Grande, Brazil.
- 60 28. Department of Epidemiology of Microbial Diseases, Yale University School of Public

61 Health, New Haven, USA.

- 62 29. Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
- 63

64 Corresponding authors:

- 65 Nuno Rodrigues Faria, PhD
- 66 Email: <u>nfaria@ic.ac.uk</u>
- 67
- 68 Julio Croda, MD PhD
- 69 Email: juliocroda@gmail.com

70 Abstract

71 The first case of COVID-19 was detected in Brazil on February 25, 2020. We report and 72 contextualize epidemiological, demographic, and clinical findings for COVID-19 cases during the first three months of the epidemic. By May 31, 2020, 514,200 COVID-19 cases, 73 including 29,314 deaths had been reported in 75.3% (4,196 of 5,570) of municipalities across 74 all five administrative regions of Brazil. Ro for Brazil was estimated at 3.1 (95% BCI 2.4-75 76 5.5), with a higher median but overlapping credible intervals compared to some other 77 seriously affected countries. A positive association between higher per-capita income and COVID-19 diagnosis was identified. Further, the severe acute respiratory infection cases with 78 79 unknown aetiology were associated with lower per capita income. Co-circulation of six 80 respiratory viruses was detected but at very low levels. These findings provide a comprehensive description of the ongoing COVID-19 epidemic in Brazil and may help guide 81 82 subsequent measures to control virus transmission.

84 Introduction

85 Coronavirus disease 2019 (COVID-19) is a severe acute respiratory infection that emerged in early December 2019 in Wuhan, China¹. The outbreak was declared a Public Health 86 Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on 87 88 January 30, 2020. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped, single-stranded positive-sense RNA virus that belongs to the 89 Betacoronavirus genus, Coronaviridae family². SARS-CoV-2 is closely related genetically to 90 91 bat-derived SARS-like coronaviruses³. Human-to-human transmission occurs primarily via respiratory droplets and direct contact, similar to human influenza viruses, SARS-CoV and 92 93 Middle East Respiratory Syndrome virus (MERS-CoV)⁴. The most commonly reported 94 clinical symptoms are fever, dry cough, fatigue, dyspnoea, anosmia, ageusia, or some combination of these^{1,4,5}. As of June 16, 2020, more than 7.9 million cases have been 95 confirmed worlwide, resulting in 434,796 deaths⁶. 96

97 Brazil declared COVID-19 as a national Public Health Emergency (PHE) on February 98 3, 2020^7 . After the development of a national emergency plan and the early establishment of molecular diagnostic facilities across Brazil's network of public health laboratories, the 99 country reported its first confirmed COVID-19 case on February 25, 2020, in a traveller 100 returning to São Paulo from northern Italy⁸. São Paulo is the largest city in South America 101 and no other Brazilian city receives a greater proportion of international flights⁹. Currently, 102 103 Brazil has one of the fastest-growing COVID-19 epidemics in the world, now accounting for 104 1,864,681 cases and 72,100 deaths, comprising over 55% of the total number of reported cases in Latin America and Caribbean (as of July 14, 2020)⁶. About 21% of Latin American 105 106 and Caribbean populations are estimated to be at risk of severe COVID-19 illness¹⁰. The 107 region has been experiencing large outbreaks, with growing epidemics in Brazil, Peru, 108 Mexico, Chile, Colombia, Panama, and possibly Venezuela and Nicaragua, amidst growing

concerns on testing capacity for COVID-19¹¹⁻¹⁴. Preparedness for laboratory surveillance of
 SARS-CoV-2 in Latin America is centred around a network of national reference influenza
 surveillance laboratories that is facing several challenges, including shortage of reagents and
 equipment¹⁵.

113 Conscious of the challenges associated with surveillance since the beginning of the 114 epidemic in Brazil, here we focus on two main objectives. First, we contextualize the 115 Brazilian SARS-CoV-2 epidemic by comparing local transmission dynamics with those 116 observed in selected other countries. Second, we use geospatial data related to confirmed 117 COVID-19 cases and severe acute respiratory infection (SARI) cases with unknown 118 aetiology to evaluate the relationship between socio-economic factors and COVID-19 119 distribution. 120 **Results**

121 Contextualizing COVID-19 data notification systems in Brazil

122 On January 22, 2020, more than one month before the first case in Brazil, the Brazilian

123 Ministry of Health implemented the REDCap platform to notify prospective suspected,

probable, and confirmed COVID-19 cases (see Methods for case definitions), as part of early 124

response to the pandemic¹⁶. By March 27, 2020, the REDCap system was discontinued (Fig. 125

126 1). Since then, mild-COVID-19 cases started to be notified on e-SUS-VE (e-SUS Vigilância

127 Epidemiológica), a new national COVID-19 notification system and hospitalised COVID-19

128 cases started to be recorded on a pre-existing SIVEP-Gripe system. The SIVEP-Gripe system

129 has been in use since 2009 (influenza H1N1 2009 pandemic) and has since centralized the

130 notification of respiratory viruses and SARI for the Brazilian Ministry of Health (Fig. 1).

131 Both the e-SUS-VE and SIVEP-Gripe include suspected and confirmed COVID-19 cases by


132 public health and private services (primary and emergency care). These two notification

133 systems (e-SUS-VE and SIVEP-Gripe) are inter-related on the Portal do COVID-19 website

134 (https://covid.saude.gov.br/), which summarises daily the aggregated counts from both platforms.

136

135



We analysed a total of 514,200 SARS-CoV-2 cases from the Portal do COVID-19 website 138

139 (SIVEP-Gripe, and e-SUS VE databases combined) that were confirmed by molecular

140 diagnostic and clinical epidemiological criteria by May 31, 2020 (see Materials and

- 141 Methods). Cases were reported in 75.3% (4,196 of 5,570) of municipalities across all five
- 142 administrative regions of Brazil and included 206,555 (40.2%) recovered patients, and 29,314
- 143 fatal (17.5%) COVID-19 cases (Fig. 2A). We further analysed a total of 1,468 confirmed

144 cases from the REDCap system, including 342 imported cases with associated travel history 145 information. After excluding cases involving with that travelled to multiple countries before 146 entering Brazil (n=56) and that had an unknown country of origin (n=16). The self-reported 147 countries of infection for cases acquired abroad until March 19, 2020 were USA (28.6%, 148 *n*=76), Italy (24.4%, *n*=65), and the United Kingdom (10.5%, *n*=28) and Spain (8.3%, *n*=22) 149 (Extended Data Fig. 1). The first reported case (SPBR1) was reported on February 25, 2020 150 in the municipality of São Paulo, the fourth most populous urban area worldwide. Following 151 the first notifications of COVID-19 in Brazil's largest population centres, we find that SARS-152 CoV-2 subsequently spread to municipalities with smaller population sizes (Fig. 2B). Until 153 May 31, 2020, most confirmed cases and deaths were reported in the states of São Paulo 154 (109,698 cases and 7,615 deaths), Rio de Janeiro (53,388 cases and 5,344 deaths), Ceará 155 (48,489 cases and 3,010 deaths) and Amazonas (41,378 cases and 2,052 deaths), which 156 together account for 49.2% of all cases and 61.5% of deaths in Brazil (Fig. 2c). 157

158 Basic reproduction number (R₀) of SARS-CoV-2 in Brazil and comparison countries

159 To estimate the basic reproduction number (R_0) of SARS-CoV-2 in Brazil, daily confirmed

160 cases in São Paulo, Rio de Janeiro, Ceará and Amazonas states were compiled from the

161 Ministry of Health (for specification of the time-windows used in the analyses see Extended

162 Data Fig. 2). For comparison, we compiled time series of confirmed cases in several

163 European countries from the Johns Hopkins Coronavirus Resource Center

164 (https://coronavirus.jhu.edu/, see also Extended Data Fig. 3). We found that São Paulo, Rio

165 de Janeiro and Amazonas were characterized by similar R_0 values of 2.9 (95% Bayesian

166 credible interval, BCI, 2.2–5.1), 2.9 (95% BCI 2.2–4.9) and 2.6 (95% BCI 2.0–4.5).

However, for Ceará, estimated R_0 was considerably lower, 1.9 (95% BCI 1.5–3.0) (Fig. 3,

168 Extended Data Fig. 1). This finding could be a result of the small window between the first

169	notified cases and the early implementation of non-pharmaceutical interventions (NPIs) in
170	this state (Supplementary Table 1, Extended Data Fig. 2). On a national scale, the
171	estimated R_0 for Brazil was slightly higher than that of the Brazilian states considered in this
172	study, with a median of 3.1 (95% BCI 2.4–5.5), and also slightly higher than R_0 values
173	estimated for other severely affected countries: Spain (2.6, 95% BCI 2.0-4.6), France (2.5,
174	95% BCI 1.9-4.4), United Kingdom (2.6, 95% BCI 2.0-5.1) and Italy (2.5, 95% BCI 2.0-
175	4.4) (Fig. 3). While the incidence curves for European countries have consistently flattened
176	and declined after the implementation of NPIs (suggesting R_0 has fallen below one), Brazil's
177	daily incidence curve has continued to increase (Fig. 2A and Extended Data Fig. 4).
178	
179	Severe acute respiratory infections (SARI) mostly reflect COVID-19 cases
180	In the early-phase of the COVID-19 epidemic in Brazil, we analysed the results for
181	other respiratory pathogens tested in Brazil as part of the differential diagnosis by Central
182	Public Health Laboratories and National Influenza Centres (Brazilian Ministry of Health)
183	obtained from a REDcap platform ¹⁷ designed for COVID-19. The respiratory viruses most
184	frequently identified between January 2020 and March 27, 2020, in patients with suspected
185	but negative diagnosis of COVID-19 were influenza A virus (347 [14.3%] of 2,429 tested
186	cases), influenza B virus (251 [10.3%] of 2,429) and human rhinovirus (136 [5.6%] of 2,429).
187	We found co-detection of SARS-CoV-2 with six other respiratory viruses, the most
188	frequently were influenza A (11 [0.5%] of 2,429) and human rhinovirus (6 [0.2%] of 2,429)
189	(Extended Fig. 7).
190	The SIVEP-Gripe system started reporting hospitalised COVID-19 cases in early
191	March 2020 (epidemiological week 10) (Fig. 4). In this system, the number of tested cases is

192 unavailable. We found that the peak of influenza confirmed cases (n=447) occurred at

193 epidemiological week 12 (15-21 March 2020). During the same week 12, we detected an 8.5-194 fold increase in total cases attributed to SARS-CoV-2 (n=3,789) and a 9.9-fold increase in 195 total cases notified as SARI with unknown aetiology (n=4,424) (Fig. 4). From January to 196 May 31, 2020, a total of 2,136 influenza cases and 272 cases caused by other respiratory 197 pathogens including human respiratory syncytial virus, human rhinovirus, adenovirus, 198 metapneumovirus were notified in the SIVEP-Gripe database. The low observed incidence of 199 influenza and other respiratory viruses may be influenced by limited testing for these viruses 200 during this period. Although NPIs may have an impact in reducing influenza virus 201 transmission, this does not necessarily reflect a lower co-circulation of other respiratory viruses¹⁸. 202 203

204 Socio-economic differences are associated with COVID-19 diagnosis

Until 31 May 2020, a total of 73,648 COVID-19 confirmed cases and 168,001 SARI cases with unknown aetiology were notified in the SIVEP-Gripe system. We hypothesized that the 2.3-fold increase of SARI cases with unknown aetiology was associated with differential access to healthcare due to socio-economic factors.

209 We focus on the Metropolitan Region of São Paulo (MRSP) that has a population of 210 23 million inhabitants across 6 sub-regions (Central, West, North, East, Southeast and 211 Southwest) and 39 municipalities (Fig. 5A). To test this hypothesis, we obtained per capita 212 income at the census tract level (typically 150-300 households) in the MRSP, based on the 213 residential address of each case. We then linked this information to each patient's final 214 diagnosis outcome: COVID-19 confirmed case or SARI with unknown aetiology. While the 215 income distribution of SARI cases with unknown aetiology was similar to that of the MRSP over the whole period (Fig. 5B), we observed that the income distribution individuals 216 217 conformed to be COVID-19-cases confirmed by laboratory and clinical criteria was initially 218 higher and decreased over time towards the distribution for the whole of the MRSP by 219 epidemiological week 21 (Fig. 5B). Importantly, we found that the log odds of one or more 220 confirmed COVID-19 case per census tract increased with per capita income in 221 epidemiological weeks 12 and 22 (likelihood ratio test [LRT] P-value <0.001 (Fig. 5B and 222 Supplementary Table 2). This provides statistical evidence of an association between 223 confirmed COVID-19 diagnosis and *per capita* income, suggesting a socio-economic 224 difference in access to COVID-19 diagnosis in the MRSP. For reference, we also provide a 225 map of per capita income (Fig. 5A) and population density in each census tract (Extended 226 Data Fig. 8).

227 We conducted a geospatial analysis to understand the distribution of relative risk of observing a COVID-19 case or an SARI cases with unknown aetiology in the MRSP, using a 228 229 Bayesian method and adjusted for spatial and non-spatial effects defined by Besag-York-Mollié model¹⁹ (Fig. 5). Our estimates show an increase in the relative risk of COVID-19 230 231 diagnosis in higher income census tracts between epidemiological weeks 12 to 21, especially 232 in the central region of the MRSP (Figs. 5A and 5C). We observed a similar trend in the 233 relative risk of SARI cases with unknown aetiology among residents of the central region. However, there is also increased probability of SARI cases with unknown aetiology in the 234 235 southwest, west, north, and south sub-regions, where income per capita is typically lower. 236 Overall, the relative risk of SARI cases with unknown aetiology is more spatially widespread in the MRSP than of confirmed COVID-19 cases (Fig. 5C). 237

The relative risk of SARI cases with unknown aetiology compared to confirmed
COVID-19 cases in the central region of the MRSP decreases through time likely as a
response to several NPIs implemented throughout the state of São Paulo (see Supplementary
Table 1). By week 16, one month after the start of the NPIs in São Paulo, we detected an
increased risk particularly of SARI cases with unknown aetiology outside the central region

243	of the MRSP, especially in the southwest region. SARI cases with unknown aetiology risk
244	was also high in the east region. By week 21, the risk remained high throughout the central
245	region and SARI cases with unknown aetiology risk decreased in the east region, possibly as
246	a result of interventions targeting the reduction of SARS-CoV-2 transmission.
247	
248	Demographics and characteristics of COVID-19 hospitalised and fatal cases in Brazil
249	Analysis of the age-sex structure of 67,180 confirmed COVID-19 cases notified on
250	the SIVEP-Gripe system revealed a high proportion (44,027 [65.5%] of 67,180) of confirmed
251	COVID-19 infections in middle or older-age individuals (≥50 years of age) and a lower
252	proportion (1,454 [2.2%] of 67,180) in younger age groups (≤ 20 years of age) (Fig. 6A). The
253	median age was 59 years (IQR = 44–72). The majority (38,654 [57.5%] of 67,180) were
254	male. Similarly, 59% (14,498 of 24,519) of COVID-19 deaths were in men, and 85% (20,916
255	of 24,519) were in people aged \geq 50 years. A total of 2.95% (1,983 of 67,180) cases were
256	reported as nosocomial transmission, defined as a COVID-19 case acquired after
257	hospitalization. Overall, 116 newborns (\leq one month old), 381 infants (\geq 1 to 12 month-old),
258	518 children (\geq 1 to 12 years old), and 258 adolescents (\geq 12 to 17 years of age) were
259	diagnosed with COVID-19. In addition, 740 patients were pregnant, 61 in the first trimester,
260	172 in the second trimester, 447 in the third trimester, and 60 had missing gestational age.
261	By 31 May 2020, 91% (67,042 of 73,649) of patients with COVID-19 notified in the
262	SIVEP-Gripe system had been hospitalized. Of these, 30.3% (22,332 of 73,649) were
263	admitted to an intensive care unit (ICU). The median length of ICU stay for COVID-19
264	patients was five days (IQR, 2-10, range: 0-65 days), based on the ICU admission and
265	discharge dates of 8,240 confirmed cases. Most symptoms reported by COVID-19 patients
266	were cough (56,681 [85.2%] of 66,514 without missing data), fever (51,312 [79.6%] of

267 65,310) and dyspnoea (51,312 [76.6%] of 65,310) (Fig. 6B). These three symptoms compose 268 part of the case definition of SARI in Brazil. In addition, 68% (40,806 of 60,400) of COVID-19 cases were hypoxic (O_2 saturation < 95%) reflecting the overall severity of cases notified 269 270 on SIVEP-Gripe (as shown in Fig. 1). The most prevalent comorbidities were cardiovascular 271 disease (23,085 [66.5%] of 34,693 without missing data) and diabetes (17,271 [54.5%] of 31,672) (Fig. 6A). Among the COVID-19 patients, older age groups tended to have a higher 272 273 proportion of comorbidities than younger age groups in different outcomes (Fig. 6C). The 274 proportions of the general Brazilian population with cardiovascular disease and diabetes are 4.2%, and 6.2%, respectively²⁰. A total of 83.7% (17,921 of 21,414 with complete 275 276 comorbidity information) confirmed COVID-19 cases had at least one comorbidity (see 277 Supplementary Table 2 for information on data completeness).

279 Discussion

280 While the COVID-19 epidemic in Brazil continues to grow, details of its transmission 281 potential and clinical and epidemiological characteristics remains poorly understood. We 282 estimate a higher median transmission potential, R_0 of 3.1 (2.4–5.5), of SARS-CoV-2 in 283 Brazil compared with Italy, UK, France, and Spain, which have point estimates of R_0 varying from 2.5 to 2.6, however the credible intervals overlap substancially. We have also observed 284 285 rapid spread of COVID-19 through the country, with more populated and better-connected 286 municipalities being affected earlier and less populated municipalities being affected at a later 287 stage of the epidemic. In the São Paulo metropolitan region, we found a higher risk of 288 diagnosed COVID-19 cases in census tracts with higher per capita income during the early-289 phase of COVID-19 epidemic but also as weeks progressed. This contrasts with the wider 290 spread of SARI cases among sub-regions with lower per capita income. Our results provide 291 new insights into the Brazilian COVID-19 epidemic and highlight the high transmission 292 potential of SARS-CoV-2 in the country, the role of its large urban centres, and the lack of 293 lockdown, the challenges in notification and non-equitable access to testing/diagnostic as 294 factors potentially contributing to the rapid and sustained spread of the epidemic in Brazil.

295 Recent estimates of R_0 at the beginning of the COVID-19 epidemic in Brazil have suggested that an infected individual would infect on average three or four others²¹. The 296 297 credible intervals of our estimates broadly overlap with these observations and are lower compared to previously published estimates for Brazil²². As a comparison, reproduction 298 number in Peru have been estimated at around 2.3 $(2.0-2.5)^{23}$. Since the start of the epidemic 299 in Brazil, several types of NPI have been adopted with varied success by the country's 27 300 301 federal units and 5,596 municipalities. Virus transmission seems to have dropped substantially in most affected states²¹ and also in the city of São Paulo²⁴. However, the 302 estimated reproduction number remains above one^{21,24}. Thus, only mitigation (and not 303

304 suppression) of the epidemic has been achieved so far, which has been linked to substantial excess deaths due to poorer health care available^{25,26}. Closer surveillance of viral 305 306 transmission at the local scales and an assessment of the impact of the different control 307 measures on COVID-19 transmission will help to determine a "optimal" mitigation strategy 308 to minimize infections and reduce healthcare demand in Brazil. Moreover, continued monitoring of the genetic diversity of the virus lineages circulating in Brazil²⁴ will be 309 important, as recent data suggests that virus diversity may play a role in virus 310 transmissibility^{27,28}. 311

We find that 65.5% of notifications in the SIVEP-Gripe system, which includes most 312 313 severe COVID-19 cases are from patients aged \geq 50 years of age. This observation is 314 remarkably similar to current estimates for Latin America¹⁰, where 65% of the individuals 315 \geq 50 years of age have been estimated to be at high risk of severe COVID-19, defined as 316 individuals with at least one condition who would require hospitalisation if infected. 317 Moreover, we find that 57% and 59% of the severe COVID-19 cases and deaths (respectively) notified in SIVEP-Gripe were male, and that the most frequent comorbidities 318 were cardiovascular disease and diabetes. Overall 84% of SIVEP-Gripe notifications had at 319 least one underlying condition; of these, 21% (*n*=9,471/45,480) are included in the working 320 321 age (16 to 65 years of age). Moreover, only 2.6% (n=1892/73,673) of the COVID-19 confirmed cases notified in the SIVEP-Gripe system include occupation. Information on 322 socio-economic determinants as well as occupation and race/ethnicity are critical²⁹ as this 323 324 allows to prioritisation of control efforts, for example towards healthcare workers and patients attending hospitals³⁰ or work settings³¹. 325

Our data uncovers a socio-economic bias in testing and diagnostics in current
 surveillance guidelines and suggests that the number of notified confirmed case counts may

328 substantially underestimate the number of cases in the general population, particularly in 329 regions of lower socio-economic status. Socio-economic differences are associated with access to healthcare³² and should be taken into account when designing targeted 330 331 interventions. We find that the proportion of SARI cases with unknown aetiology to 332 confirmed COVID-19 cases has increased across the entire country (as of June 15, 2020, the 333 number of notified SARI cases with unknown aetiology is nearly 2-fold greater than 334 confirmed COVID-19 cases). Based on clinical and epidemiological grounds, it is likely that 335 many SARI cases with unknown aetiology are caused by SARS-CoV-2. In order rigorously 336 establish the contribution of non-SARS-CoV-2 infections to the SARI cases, we would need 337 additional denominator data to understand the level of testing for these viruses, i.e., the 338 negative test results. Our findings with regards to socio-economic bias are likely to apply to 339 other states and regions of Brazil and highlight the importance of scaling up surveillance and 340 laboratory capacity within Latin America. Indeed, the largest Brazilian serosurvey conducted to date suggests that undetedected cases may be seven times higher than reported cases³³. 341 342 We further show that SARI cases with unknown aetiology are associated with lower 343 socio-economic status in the Metropolitan Region of São Paulo. The socio-economic 344 disparities observed here were particularly evident at the beginning of the outbreak (Fig. 5B). 345 This can be explained in part by (i) the high proportion of early cases in returning travellers 346 with higher income and better access to private laboratories for diagnostics, and (ii) the more 347 limited access to freely available diagnostic screening. For example, between February 25 348 and March 18, 2020, two thirds (586 [66.9%] of 876) of diagnostic tests were performed in private medical laboratories where costs varied typically between 300-690 Brazilian Reais 349

351 the epidemic in lower income neighbourhoods is most likely underestimated. In New York

350

(BRL) (for context, current minimum monthly salary is 1,045 BRL). Thus, the true burden of

352 City, for example, poorer neighbourhoods had higher disease burden, driven in part by the

movement of essential workers using public transport during the pandemic³⁴. Data-driven 353 354 analyses are urgently needed to help tackling health inequities during the ongoing epidemic 355 in Brazil. Strategies to evaluate and control transmission should consider differential assess to 356 COVID-19 diagnosis for lower income populations, changes in notification systems and delays in reporting which are key to accurately determine rates of epidemic growth³⁵. 357 358 Innovative infectious disease surveillance approaches such as those obtained from aggregated 359 mobility data, when used properly, could help supporting public health actions across the COVIV-19 epidemic³⁶⁻³⁹. 360

361 Epidemics of COVID-19 and influenza seem to have occurred simultaneously in 362 Brazil (Fig.4 and Extended Data Figure 7) and symptoms overlap between the two infections. We detected co-circulation of eight other respiratory viruses, the most common 363 364 respiratory infections were influenza A and B, and human rhinovirus. We also detected 365 multiple co-detection of SARS-CoV-2 with other respiratory viruses, such as influenza A, B and human metapneumovirus, which have also been reported elsewhere^{40,41}. Although, co-366 infections with other respiratory viruses have been reported in other countries⁴²⁻⁴⁴, no 367 368 difference in clinical disease severity between cases with and without viral co-infection has been observed thus far⁴⁵. The co-circulation of other respiratory pathogens highlights the 369 need of scaling up laboratory and molecular screening of SARS-CoV-2 and other respiratory 370 viruses in public laboratories across Brazil¹⁵. Continued molecular and genomic surveillance 371 372 will be important to determine patterns of virus transmission and guide public health measures in forthcoming phases of the epidemic $^{24,46-48}$. 373

There are several limitations to this study. First, detailed individual-level data were only available for REDcap and SIVEP-Gripe systems, in which many cases had incomplete documentation, particularly regarding comorbidities. Second, our socio-economic analysis was based partially on ecological inference, using the *per capita* income in the census tract of

378 residence (tather than the actual income of the patients), and assuming the same denominator 379 for each census tract (~300 households). We emphasize that our spatial analysis is prone to metholodological constraints caused by ecological fallacy and the modifiable areal unit 380 381 problem. These constraints are inherent to any spatial analysis of aggregated data. Despite the 382 above-mentioned limitation, census tract corresponds to small areas of analysis, of no more 383 than 300 households but often less than that. Social science literature on Brazil not only 384 highlights the country's socio-economic inequality but also how it is spatially pronounced, 385 for that reason, census tract remains a useful tool to infer per capita income in the absence of 386 individual-level data. In addition, our databases were predominantly composed of 387 hospitalised COVID-19 patients, and we were unable to evaluate the rate of hospitalisation 388 among the different socio-economic status. In the future, robust modelling of the 389 relationships between socio-economic factors and disease severity will require a data 390 collection system with detailed information on symptoms/signs and comorbidities both in 391 severe and non-severe cases. Finally, our retrospective study has focused predominantly on 392 symptomatic patients that presented or were referred to health services for testing. Therefore, 393 we are unable and do not attempt to describe the full spectrum of disease, nor can we describe 394 the full epidemiological picture of this epidemic.

In conclusion, we have provided a comprehensive assessment of COVID-19
notification and transmission in Brazil. Our findings provide important context for diagnostic
screening and health-care planning, and for future precision studies focussing on the impact
of non-pharmaceutical and pharmaceutical interventions, and the effect of social health
determinats on COVID-19 transmission.

400 Methods

401 Ethical approval and case definitions

This retrospective national study was supported by the Brazilian Ministry of Health and
ethical approval was provided by the national ethical review board (Comissão Nacional de
Ética em Pesquisa, CONEP), protocol number CAAE 30127020.0.0000.0068.

A patient presenting with an acute respiratory syndrome (fever and at least one
sign/symptom of respiratory illness), and (i) history of travel to a location with community
transmission of COVID-19, or, (ii) contact with a confirmed or probable COVID-19 case in
the 14 days preceding symptom onset, or (iii) absence of an alternative diagnosis that
completely explains the clinical presentation⁶ was considered as suspected COVID-19 case.

410 Initially, a traveller was considered a suspected case only when arriving from China, 411 although the definition of suspected cases associated with travel later included Japan, 412 Singapore, South Korea, North Korea, Thailand, Vietnam and Cambodia (February 21, 413 2020), Italy, Germany, Australia, United Arab Emirates, Philippines, France, Iran and 414 Malaysia (February 25, 2020), the USA, Canada, Switzerland, United Kingdom and 4 415 additional countries (March 3, 2020). From March 9, 2020 onwards, the Ministry of Health 416 decided to start testing all hospitalised patients with severe respiratory symptoms, regardless 417 of travel history.

418 Contact with a confirmed or probable COVID-19 case was defined as face-to-face or 419 direct contact with a COVID-19 case, or direct contact in a health-care setting. Moreover, 420 patients reporting travel to an affected country in the preceding 14 days were considered 421 imported cases. Cases not meeting this criterion were considered to be due to local 422 transmission.

423	Suspected COVID-19 cases were confirmed by laboratory testing (i.e., molecular
424	diagnostic with real-time quantitative PCR), or by clinical-epidemiological criteria. In the
425	latter case, the classification is used when laboratory testing is inconclusive or unavailable, as
426	recommended by Brazilian Ministry of Health guidelines, dated April 6, 2020 ⁴⁹ , and by the
427	World Health Organization interim guidance, dated March 25, 2020 ⁵⁰ .
428	
429	Individual-level notification of COVID-19 and SARI cases with unknown aetiology from
430	Brazil
431	To investigate individual-level diagnostic, demographic, self-reported travel history,
432	place of residence and likely place of infection, differential diagnosis for other respiratory
433	pathogens, as well as clinical details, including comorbidities, we collected three
434	epidemiological data sources: (i) $n=67,344$ suspected and $n=1,468$ confirmed cases notified
435	to the REDCap database from February 25 to March 25, 2020; (<i>ii</i>) <i>n</i> =73,637 confirmed
436	SIVEP-Gripe (Sistema de Informação de Vigilância Epidemiológica da Gripe) from March 1
437	to May 31, 2020 (available at https://shiny.hmg.saude.gov.br/dataset); and (iii) n=514,200
438	confirmed cases from aggregated data daily released at the Portal do COVID-19 (Brazilian
439	Health Ministry) from February 25 to May 31, 2020 (available at <u>www.covid.saude.gov.br/</u>).
440	SIVEP-Gripe system notifies severe acute respiratory infections (SARI), which can be
441	defined as an acute respiratory infection with onset within the last 10 days of fever (\geq 38° C)
442	and cough, and typically requires hospitalization (see also Fig. 1A).
443	
444	Basic reproduction number (R_0) estimation
445	We estimated the basic reproduction number (R_0) for SARS-CoV-2 using time series
446	of confirmed COVID-19 cases at the national and state level: São Paulo, Rio de Janeiro,

447 Ceará and Amazonas (Extended Data Fig. 1). To avoid the impact of non-pharmaceutical 448 interventions (NPI) on R_0 estimates, only data points up to 14 days after the implementation of the strictest interventions were used. As lockdown was not imposed in Brazil, the strictest 449 450 measure was considered closure of non-essential commerce. For European countries, the date 451 of lockdown was used as NPI date. NPI dates for Brazilian states were collected from state 452 decrees. For Brazil as a whole the NPI date for São Paulo state was used, as by that point 453 most states in Brazil had already closed non-essential commerce. For the European countries, 454 lockdown dates were collected from https://www.covid19healthsystem.org/mainpage.aspx.

455 To test the estimation routine and provide international context, this analysis was replicated on equivalent time series from Italy, Spain, France, and the United Kingdom. 456 Aggregated USA and China epidemiological data were not included due to possible 457 458 heterogeneity within each country. Daily counts of confirmed cases were modelled with a 459 negative binomial distribution with a mean equal to a fixed portion, ρ , of the total daily 460 number of cases in an exponential model of incidence. The functional form of the incidence model is $\rho R_0 \gamma i_0 e^{(R0 - 1)\gamma t}$, which comes from an exponential approximation of the early 461 462 dynamics where individuals cease to be infectious at a rate γ . The factor of $\rho R_0 \gamma$ accounts for the partial observation of the incidence. In this analysis was not accounted for the delay 463 464 between infection and reporting.

Since ρ and i_0 only appear together, they were unidentifiable, we combine them into a single parameter, ξ . This identifiability issue prevents us from estimating the prevalence without additional information to inform either i_0 or ρ . The analysis was carried out in a Bayesian framework with an uninformative prior distribution on R_0 and an informative prior on the removal rate, all other parameters had weakly-informative prior distributions (details in the **Supplementary Information**, pp. 2-3). The informative prior ensured an individual is infectious for an average of 5 to 14 days⁵¹ (**Supplementary Information**, Fig. 5-6). Standard 472 diagnostics were used to check whether the Markov Chain Monte Carlo (MCMC) samples

473 were satisfactory. Full details of the model used, the estimation process and convergence of

474 MCMC chains can be found in the **Supplementary Information**, pp. 2-3.

475

476 <u>Geospatial analysis of COVID-19 cases and socio-economic status</u>

477 The average household *per capita* income for the Metropolitan Region of São Paulo
478 (MRSP) was retrieved at the census tract level from the 2010 census

479 (https://censo2010.ibge.gov.br/). We geocoded 24,063 COVID-19 cases and 32,914 SARI

480 cases with unknown aetiology from MRSP, which were notified until May 28, 2020. The

481 geo-coding was based on self-reported residential address or postal codes using the Galileo

482 algorithm 52 and coordinates were confirmed using the Google API.

To elucidate the distribution of COVID-19 cases and SARI cases with unknown 483 aetiology cases, we mapped the mean relative risk of COVID-19 and SARI cases with 484 485 unknown aetiology at the census tract level for MRSP for three epidemiological weeks (12, 486 16, and 21). As the observation process was a confounding process and without additional 487 assumptions (e.g. covariates), we cannot disentangle an increase in prevalence from an 488 increase in case ascertainment. The cumulative number of cases in each tract is modelled as a 489 Poisson random variable with a mean specified by the expected number of cases under a null 490 model adjusted by tract specific risk due to spatial and non-spatial effects: the Besag-York-Mollié model¹⁹. Estimates of the risk of COVID-19 diagnosis or SARI cases with unknown 491 492 aetiology were obtained using approximate Bayesian methods (Integrated Nested Laplace 493 Approximation). A complete specification of the model and the computational methodology 494 can be found in the Supplementary Information, pp.1-2.

495 The association between final diagnostic category (COVID-19 or SARI cases with 496 unknown aetiology) and socio-economic status in the subset of cases in the MRSP with 497 geocoded residential information was evaluated using logistic regression models. We focused 498 on the cases in epidemiological weeks 12, 16 and 22. Within each of those weeks, if a census 499 tract reported any COVID-19 or SARI cases with unknown aetiology, we calculated the 500 proportion of the number of COVID-19 cases. Since most census tracts reported only one case each week, the proportion of COVID-19 of each census tract were mostly either 0 or 1 in 501 502 a given week. For this reason, we defined two categories: (i) the census tract only reported 503 SARI of unknown etiology, i.e. no COVID-19 cases, (ii) the census tract reported at least one 504 COVID-19 case in the week. We used these two categories as the binary response, and 505 applied logistic regression models to investigate whether income per capita was associated 506 with this response. The analyses were adjusted by the logarithm of the population sizes and 507 the longitude and latitude coordinates of the census tracts. The analysis was performed 508 individually for each of epidemiological weeks 12, 16 and 22. Further details of this analysis 509 can be found in the Supplementary Information, pp. 1-2.

5	1	1	Data	avail	lah	ilií	v
v	•	•	Data	avan	an	1110	۶J

512	Datasets of clinical and laboratory data presented in the current study from SIVEP-Gripe and
513	Portal do COVID-19 database are available at https://doi.org/10.5061/dryad.n8pk0p2sp. The
514	REDCap database and geolocation information are available from the corresponding authors
515	upon request and ethical approval.
516	
517	Code availability
518	The custom code used in this study is avaiable at https://doi.org/10.5061/dryad.n8pk0p2sp.
519	
520	Author contributions
521	W.M.S, L.F.B, D.S.C, R.H.M.P, C.A.P, J.C, J-P.C, V.H.N, A.E.Z, J.M, F.C.S.S, P.S.A, F.G,
522	A.A.S-S, B.G, C-H.W, S.L, N.G, S.B.O, K.V.P, M.C.T.D.B, V.B.G.P, C.K.V.B, F.G,
523	W.A.F.A, F.F.S.T.F, E.M.M and W.K.O collected the epidemiological, spatial and clinical
524	data and processed statistical data. N.R.F, W.M.S, L.F.B, C-H.W, J-P.C, D.C.S, R.H.M.P,
525	J.M, E.C.S, P.M, S.L, L.A, A.A.S-S, G.L, A.T, M.F.V-G, M.U.G.K, R.S.A, N.A, P.M, O.J.B,
526	I.O.M.S, N.G, G.L, O.G.P, A.E.Z, M.L.N, and J.C interpreted the results and wrote the
527	manuscript. All authors read and revised the final manuscript. W.M.S, L.F.B, J.C, and N.R.F
528	are responsible for summarising epidemiological and clinical data.
529	
530	Declaration of interests
531	The authors declare no competing interests.
532	

533 Acknowledgments

534 The authors thank the clinicians and epidemiologists for technical support and Lucy Matkin 535 for technical assistance. This work was supported by a FAPESP (2018/14389-0) and Medical 536 Research Council and CADDE partnership award (MR/S0195/1), (http://caddecentre.org/). 537 WMS is supported by the São Paulo Research Foundation, Brazil (No. 2017/13981-0 and 538 2019/24251-9). NRF is supported by a Wellcome Trust and Royal Society Sir Henry Dale 539 Fellowship (204311/Z/16/Z). OJB was funded by a Sir Henry Wellcome Fellowship funded 540 by the Wellcome Trust (206471/Z/17/Z). VHN and CAP were supported by FAPESP (2018/12579-7). AEZ and BG are supported by Oxford Martin School. The funders had no 541 542 role in study design, data collection and analysis, decision to publish or preparation of the 543 manuscript.

545 References

- 1 Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in
- 547 Wuhan, China. *Lancet* **395**, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).
- 548 2 Coronaviridae Study Group of the International Committee on Taxonomy of, V. The
- 549 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-
- nCoV and naming it SARS-CoV-2. *Nature Microbiology*, doi:10.1038/s41564-020-

551 0695-z (2020).

- 552 3 Lu, R. *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus:
- implications for virus origins and receptor binding. *Lancet* **395**, 565-574,
- doi:10.1016/S0140-6736(20)30251-8 (2020).
- Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England Journal of Medicine*, doi:10.1056/NEJMoa2002032 (2020).
- 557 5 Livingston, E. & Bucher, K. Coronavirus Disease 2019 (COVID-19) in Italy. *Jama*,
 558 doi:10.1001/jama.2020.4344 (2020).
- 559 6 World-Health-Organization. Coronavirus disease (COVID-2019) situation reports
- 560 (2020). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus561 2019/situation-reports
- 5627Croda, J. et al. COVID-19 in Brazil: advantages of a socialized unified health system
- and preparation to contain cases. *Revista da Sociedade Brasileira de Medicina*

564 *Tropical* **53**, e20200167, doi:10.1590/0037-8682-0167-2020 (2020).

- 565 8 Jesus, J. G. et al. Importation and early local transmission of COVID-19 in Brazil,
- 566 2020. *Revista do Instituto de Medicina Tropical de Sao Paulo* **62**, e30,
- 567 doi:10.1590/s1678-9946202062030 (2020).

568 9 Candido, D. S., Watts, A., Abade, L., Kraemer, M. U.G., Pybus, O. G., Croda, J., de Oliveira, W., Khan, K., Sabino, E. C., Faria, N. R. Routes for COVID-19 importation 569 in Brazil. Journal of Travel Medicine in press (2020). 570 571 10 Clark, A., Jit, M., Warren-Gash, C., Guthrie, B., Wang, H. H. X., Mercer, S. W., Sanderson, C., McKee, M., Troeger, C., Ong, K. L., Checchi, F., Perel, P., Joseph, S., 572 573 Gibbs, H. P., Banerjee, A., Eggo, R. M., Centre for the Mathematical Modelling of 574 Infectious Diseases COVID-19 working group. Global, regional, and national 575 estimates of the population at increased risk of severe COVID-19 due to underlying 576 health conditions in 2020: a modelling study. The Lancet Global health https://doi.org/10.1016/ S2214-109X(20)30264-3 (2020). 577 578 11 Burki, T. COVID-19 in Latin America. The Lancet Infectious Diseases 20, 547-548, 579 doi:10.1016/S1473-3099(20)30303-0 (2020). 12 Cimerman, S., Chebabo, A., Cunha, C. A. D. & Rodriguez-Morales, A. J. Deep 580 impact of COVID-19 in the healthcare of Latin America: the case of Brazil. The 581 582 Brazilian Journal of Infectious Diseases 24, 93-95, doi:10.1016/j.bjid.2020.04.005 583 (2020). 584 13 Ezequiel, G. et al. The COVID-19 Pandemic: A Call to Action for Health Systems in 585 Latin America to Strengthen Quality of Care. Int J Qual Health Care, 586 doi:10.1093/intqhc/mzaa062 (2020). 587 14 Miller, M. J., Loaiza, J. R., Takyar, A. & Gilman, R. H. COVID-19 in Latin America: 588 Novel transmission dynamics for a global pandemic? PLoS Negl Trop Dis 14, e0008265, doi:10.1371/journal.pntd.0008265 (2020). 589 590 15 Andrus, J. K. et al. Perspectives on Battling COVID-19 in Countries of Latin America 591 and the Caribbean. The American Journal of Tropical Medicine and Hygiene, 592 doi:10.4269/ajtmh.20-0571 (2020).

- 593 16 Croda, J. H. R. & Garcia, L. P. Immediate Health Surveillance Response to COVID-
- 594 19 Epidemic. *Epidemiol Serv Saude* **29**, e2020002, doi:10.5123/S1679-

59549742020000100021 (2020).

- Harris, P. A. *et al.* The REDCap consortium: Building an international community of
 software platform partners. *J Biomed Inform* 95, 103208,
- 598 doi:10.1016/j.jbi.2019.103208 (2019).
- 599 18 WHO. Influenza update (2020).
- https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_s
 urveillance/en/ (2020).
- Besag, J., York, J. & Mollié, A. Bayesian image restoration, with two applications in
 spatial statistics. *Annals of the Institute of Statistical Mathematics* 43, 1-20,
- 604 doi:10.1007/BF00116466 (1991).
- 605 20 IBGE. Pesquisa nacional de saúde (2013) Brasil e grandes regiões. (2015).
- Mellan, T. A. *et al.* Report 21: Estimating COVID-19 cases and reproduction number
 in Brazil. *medRxiv*, 2020.2005.2009.20096701, doi:10.1101/2020.05.09.20096701
 (2020).
- 609 22 Caicedo-Ochoa, Y., Rebellon-Sanchez, D. E., Penaloza-Rallon, M., Cortes-Motta, H.
- 610 F. & Mendez-Fandino, Y. R. Effective Reproductive Number estimation for initial
- 611 stage of COVID-19 pandemic in Latin American Countries. *International Journal of*
- 612 *Infectious Diseases* **95**, 316-318, doi:10.1016/j.ijid.2020.04.069 (2020).
- 613 23 Munayco, C. V. *et al.* Early transmission dynamics of COVID-19 in a southern
- hemisphere setting: Lima-Peru: February 29th-March 30th, 2020. *Infect Dis Model*,
- 615 doi:10.1016/j.idm.2020.05.001 (2020).
- 616 24 Candido, D. d. S. et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil.
- 617 *medRxiv*, 2020.2006.2011.20128249, doi:10.1101/2020.06.11.20128249 (2020).

- Ferguson, N. *et al.* Report 9: Impact of non-pharmaceutical interventions (NPIs) to
 reduce COVID19 mortality and healthcare demand. Imperial College COVID-19
 Response Team (2020).
- 621 26 Walker, P. G. T. *et al.* The impact of COVID-19 and strategies for mitigation and
 622 suppression in low- and middle-income countries. *Science*,
- 623 doi:10.1126/science.abc0035 (2020).
- 624 27 Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theilr, J., Abfalterer, W.,
- 625 Foley, B., Giorgi, E. E., Bhattacharya, T., Parker, M. D., Partrridgee, D. G., vans, C.
- 626 M., Freeman, T. M., de Silva, T. I., on behald of the Sheffield. COVID-19 Genomics
- 627 Group, LaBranche, C. C., Montefiori, D. C. Spike mutation pipeline reveals the
- 628 emergence of a more transmissible form of SARS-CoV-2. *bioRxiv*
- 629 https://doi.org/10.1101/2020.04.29.069054 (2020).
- 28 Zhang, L. et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1

631 shedding and increases infectivity. *bioRxiv*, 2020.2006.2012.148726,

- 632 doi:10.1101/2020.06.12.148726 (2020).
- 633 29 Khalatbari-Soltani, S., Cumming, R. G., Delpierre, C. & Kelly-Irving, M. Importance
- of collecting data on socioeconomic determinants from the early stage of the COVID-
- 635 19 outbreak onwards. *J Epidemiol Community Health*, doi:10.1136/jech-2020-214297
- 636 (2020).
- 637 30 Rivett, L. *et al.* Screening of healthcare workers for SARS-CoV-2 highlights the role
 638 of asymptomatic carriage in COVID-19 transmission. *eLife* 9,
- 639 doi:10.7554/eLife.58728 (2020).
- 640 31 Park, S. Y. et al. Coronavirus Disease Outbreak in Call Center, South Korea.
- 641 *Emerging Infectious Diseases* **26**, doi:10.3201/eid2608.201274 (2020).

- 642 32 Pereira, R. H. et al. Mobilidade urbana e o acesso ao Sistema Único de Saúde para
- 643 casos suspeitos e graves de Covid-19 nas vinte maiores cidades do Brasil. 14 Diretoria
- 644 de Estudos e Politicas Regionais, Urbanas e Ambientais, IPEA (2020).
- 645 33 Silveira, M. et al. Repeated population-based surveys of antibodies against SARS-
- 646 CoV-2 in Southern Brazil. *medRxiv*, 2020.2005.2001.20087205,
- 647 doi:10.1101/2020.05.01.20087205 (2020).
- Sy, K. T. L., Martinez, M. E., Rader, B. & White, L. F. Socioeconomic disparities in
 subway use and COVID-19 outcomes in New York City. *medRxiv*,
- 650 2020.2005.2028.20115949, doi:10.1101/2020.05.28.20115949 (2020).
- 651 35 Dehning, J. *et al.* Inferring change points in the spread of COVID-19 reveals the
- effectiveness of interventions. *Science*, doi:10.1126/science.abb9789 (2020).
- Buckee, C. O. *et al.* Aggregated mobility data could help fight COVID-19. *Science* **368**, 145-146, doi:10.1126/science.abb8021 (2020).
- de Oliveira, S. B. *et al.* Monitoring social distancing and SARS-CoV-2 transmission
- 656 in Brazil using cell phone mobility data. *medRxiv*, 2020.2004.2030.20082172,
- 657 doi:10.1101/2020.04.30.20082172 (2020).
- 658 38 Kraemer, M. U. G. et al. The effect of human mobility and control measures on the
- 659 COVID-19 epidemic in China. *Science* 368, 493-497, doi:10.1126/science.abb4218
 660 (2020).
- 861 39 Nouvellet, P. *et al.* Report 26: Reduction in mobility and COVID-19 transmission.
 862 Imperial College COVID-19 Response Team (2020).
- Wu, X. *et al.* Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with
 Pneumonia, China. *Emerging Infectious Diseases* 26, doi:10.3201/eid2606.200299
 (2020).

- Kim, D., Quinn, J., Pinsky, B., Shah, N. H. & Brown, I. Rates of Co-infection
- 667 Between SARS-CoV-2 and Other Respiratory Pathogens. *JAMA*,
- 668 doi:10.1001/jama.2020.6266 (2020).
- 669 42 Cuadrado-Payan, E. *et al.* SARS-CoV-2 and influenza virus co-infection. *Lancet* 395,
 670 e84, doi:10.1016/S0140-6736(20)31052-7 (2020).
- 43 Wu, X. *et al.* Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with
- 672 Pneumonia, China. *Emerging Infectious Diseases* **26**, 1324-1326,
- 673 doi:10.3201/eid2606.200299 (2020).
- 44 Zheng, X. et al. Co-infection of SARS-CoV-2 and Influenza virus in Early Stage of
- 675 the COVID-19 Epidemic in Wuhan, China. *The Journal of infection*,
- 676 doi:10.1016/j.jinf.2020.05.041 (2020).
- Asner, S. A. *et al.* Clinical disease severity of respiratory viral co-infection versus
 single viral infection: a systematic review and meta-analysis. *PloS One* 9, e99392,
- 679 doi:10.1371/journal.pone.0099392 (2014).
- 680 46 Black, A., MacCannell, D. R., Sibley, T. R. & Bedford, T. Ten recommendations for
- supporting open pathogen genomic analysis in public health. *Nature Medicine*,
- 682 doi:10.1038/s41591-020-0935-z (2020).
- 68347Deng, X. *et al.* Genomic surveillance reveals multiple introductions of SARS-CoV-2
- 684 into Northern California. *Science*, doi:10.1126/science.abb9263 (2020).
- 685 48 Lu, J. *et al.* Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China.
- 686 *Cell* **181**, 997-1003 e1009, doi:10.1016/j.cell.2020.04.023 (2020).
- 687 49 Ministerio da Saude, B. Coronavirus COVID-19 Diretrizes para Diagnostico e
- 688Tratamento da COVID-19. (2020).
- 689 50 WHO. *COVID-19 coding in ICD-10*,
- 690 <<u>https://www.who.int/classifications/icd/COVID-19-coding-icd10.pdf?ua=1</u>>(2020).

691	51	Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019.
692		Nature, doi:10.1038/s41586-020-2196-x (2020).
693	52	Medel, C. H., Catalan, C. C. Vidou, M. A. F., Perez, E. S. The Galileo Ground
694		Segment Integrity Algorithms: Design and Performance. International Journal of
695		Navigation and Observation 2008 (2008).
696		
697		
698		
699		
700		
701		
702		
703		
704		
705		
706		
707		
708		
709		
710		
711		
712		

713 Legend figures

714

715 Fig. 1 | Timeline of national COVID-19 notification systems in Brazil. The REDCap 716 system operated between late January until March 25, 2020. Aggregated numbers from e-717 SUS-VE and SIVEP-Gripe data for mild and hospitalised COVID-19 cases, respectively, are 718 updated on a daily basis at the Portal do COVID-19 website (https://covid.saude.gov.br/). 719 720 Fig. 2 | COVID-19 epidemiology in Brazil. a. Number of COVID-19 cases (blue filled line) 721 and deaths (blue dashed line) reported to the Ministry of Health (Portal do COVID-19 722 website), and number of COVID-19 confirmed cases (salmon filled line) and number of 723 SARI with unknown aetiology (salmon dashed line) reported to the SIVEP-Gripe database. b. 724 First COVID-19 cases by date and Brazilian municipal population size based on the Ministry 725 of Health, from March 28, 2020. Each circle represents the first confirmed COVID-19 case in 726 the municipality (n=4,196 Brazilian municipalities). c. Map coloured according to the 727 number of confirmed COVID-19 cases per state reported to the Ministry of Health (Portal do 728 COVID-19 website). Circle sizes are proportional to the number of reported COVID-19 729 deaths in each federal unit. SPBR1 is the first detected SARS-CoV-2 infection in Brazil⁸. 730 The codes for the 27 federal units in Brazil were: Acre (AC), Alagoas (AL), Amapá (AP), 731 Amazonas (AM), Bahia (BA), Ceará (CE), Distrito Federal (DF), Espírito Santo (ES), Goiás 732 (GO), Maranhão (MA), Mato Grosso (MT), Mato Grosso do Sul (MS), Minas Gerais (MG), 733 Pará (PA), Paraíba (PB), Paraná (PR), Pernambuco (PE), Rio de Janeiro (RJ), Rio Grande do 734 Norte (RN), Rio Grande do Sul (RS), Rondônia (RO), Roraima (RR), Santa Catarina (SC), 735 São Paulo (SP), Sergipe (SE) and Tocantins (TC).

Fig.3 | Estimated R_{θ} values for four Brazilian states and selected countries. Left, R_{θ} for the Amazonas, Ceará, Rio de Janeiro and São Paulo states. Right, R_{θ} for Brazil, France, Italy, Spain and United Kingdom. Daily number of infections used in each analysis can be found in **Extended Figs. 3-4**. Daily number of infections and prior distributions can be found in **Extended Figs. 5-6**.

742

Fig. 4 | COVID-19, SARI with unknown aetiology and influenza. Red and orange lines
indicate cases notified in 2020, blue lines indicate cases notified in 2016 for influenza (filled
blue line) and SARI cases with unknown aetiology (dashed blue line). Grey lines indicate

influenza and SARI cases with unknown aetiology for 2017, 2018 and 2019.

747

748 Fig. 5 | COVID-19 diagnosis and socio-economic factors in the Metropolitan Region of 749 São Paulo. A. Spatial distribution of income per capita of MRSP based on census tract of residence. B. Distribution of household per capita income based on census tract of residence 750 751 for COVID-19 cases and SARI cases with unknown aetiology. The distribution of average per capita income for MRSP as a whole, weighted by population size, is shown on the left. 752 753 C. Posterior mean relative risk of COVID-19 confirmed diagnosis (upper panels) and SARI 754 cases with unknown aetiology (lower panels) for epidemiological weeks 12 (preimplementation of NPI in São Paulo state, and weeks 16 and 21 (post-implementation of NPI 755 756 in São Paulo state) (see Methods for details). 757 758 Fig. 6 | Age-sex structure and clinical features of confirmed COVID-19 cases notified on 759 the SIVEP-Gripe system. A. Age classes are shown on the left of the panel. On-going cases

760 were those still active on the SIVEP-Gripe database and without a recorded clinical outcome

- 761 (death or recovered). **B.** Symptoms, signs and comorbidities of confirmed COVID-19 cases.
- 762 C. Comorbidities among confirmed COVID-19 cases according to age groups and outcome.
- 763 Confirmed COVID-19 cases with complete comorbidity and outcome (death or recovery)
- information (n = 15,720). Confirmed COVID-19 cases with complete information on
- comorbidities and ITU admission (n = 19,409). Horizontal axes show the proportion of
- 766 patients in each age/outcome stratified with each of the comorbidities recorded.